| Literature identifier | Study type | Test dosage | Effective dosage | Endocrine-mediated endpoints | Systems-level perturbations |
|---|---|---|---|---|---|
| PMID:29718108 | IVTH | 0.0001 M | 0.0001 M | Increased progesterone levels | Reproductive endocrine-mediated perturbations |
| IVTH | 0.00003 M | 0.00003 M | Affects steroid metabolism | Metabolic endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVTH | 0.00003 M | 0.00003 M | Increased 17-OH-progesterone levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.00003 M | 0.00003 M | Increased pregnenolone levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.00003 M | 0.00003 M | Increased 17-OH-pregnenolone levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.00003 M | 0.00003 M | Increased progesterone levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.00045 M | 0.00045 M | Increased 17-OH-pregnenolone levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.00045 M | 0.00045 M | Decreased androstenedione levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.00045 M | 0.00045 M | Increase in corticosterone levels | Neurological endocrine-mediated perturbations | |
| IVTH | 0.00045 M | 0.00045 M | Increased 17-OH-progesterone levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.00045 M | 0.00045 M | Increased androstenedione levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.00045 M | 0.00045 M | Increased pregnenolone levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.00045 M | 0.00045 M | Increased progesterone levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.00045 M | 0.00045 M | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.00045 M | 0.00045 M | Affects steroid metabolism | Metabolic endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVTH | 0.0000003 M | - | No significant effects observed | - | |
| IVTH | 0.000003 M | 0.000003 M | Increased 17-OH-progesterone levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.000003 M | 0.000003 M | Affects steroid metabolism | Metabolic endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVTH | 0.00001 M | 0.00001 M | Increased 17-OH-progesterone levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.00001 M | 0.00001 M | Affects steroid metabolism | Metabolic endocrine-mediated perturbations;Reproductive endocrine | |
| IVTH | 0.0003 M | 0.0003 M | Increased 17-OH-progesterone levels | ||
| IVTH | 0.0003 M | 0.0003 M | Increased pregnenolone levels | ||
| IVTH | 0.0003 M | 0.0003 M | Increased progesterone levels | ||
| IVTH | 0.0003 M | 0.0003 M | Increased 17-OH-pregnenolone levels | ||
| IVTH | 0.0003 M | 0.0003 M | Affects steroid metabolism | ||
| IVTH | 0.0003 M | 0.0003 M | Decreased testosterone levels | ||
| IVTH | 0.0001 M | 0.0001 M | Increased pregnenolone levels | ||
| IVTH | 0.0001 M | 0.0001 M | Increased 17-OH-progesterone levels | ||
| IVTH | 0.0001 M | 0.0001 M | Affects steroid metabolism | ||
| IVTH | 0.0001 M | 0.0001 M | Increased 17-OH-pregnenolone levels |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.